Is Clindamycin registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 18 valid registrations of Clindamycin, including AVOCIN (2 %, Cream, SAR 40.45); AVOCIN (1 %, Solution, SAR 15.05); Avocin (300 mg, Capsule, hard, SAR 34.85); Avocin (150 mg, Capsule, hard, SAR 19.25); CLINDASOL 10MG-ML Solution (10 %, Solution, SAR 27.10).

Is Clindamycin approved by the US FDA?

Drugs@FDA lists 118 application product lines for Clindamycin, including CLEOCIN HYDROCHLORIDE (Prescription); CLEOCIN PHOSPHATE (Prescription); CLEOCIN (Prescription); CLEOCIN T (Prescription); CLEOCIN PHOSPHATE (Prescription).

Is Clindamycin on the WHO Model List of Essential Medicines?

Yes — 6.2.1. Access group antibiotics (core list): First choice: Necrotising fasciitis; Second choice: Bacterial infection of joint; Second choice: Osteomyelitis or osteitis.

Are there safety signals or safety updates for Clindamycin?

EMA PRAC: 4 entries; US FDA: 11 entries (latest 2026-09-01).

Active substance

Clindamycin

SFDA 31
US FDA 118
Health Canada 25
US price lines 17
NHS prices 6
WHO EML 1
Safety 15

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
AVOCIN	2 %	Cream · Vaginal use	1 Bottle	SAR 40.45	Generic · Prescription	Middle East Pharmaceutical Industries Co Ltd Avalon Pharma	Valid
AVOCIN	1 %	Solution · Topical	1 Bottle	SAR 15.05	Generic · Prescription	Middle East Pharmaceutical Industries Co Ltd Avalon Pharma	Valid
Avocin	300 mg	Capsule, hard · Oral use	20 Blister	SAR 34.85	Generic · Prescription	Middle East Pharmaceutical Industries Co Ltd Avalon Pharma	Valid
Avocin	150 mg	Capsule, hard · Oral use	20 Blister	SAR 19.25	Generic · Prescription	Middle East Pharmaceutical Industries Co Ltd Avalon Pharma	Valid
CLINDASOL 10MG-ML Solution	10 %	Solution · Topical	1 Bottle	SAR 27.10	Generic · Prescription	Dallah Pharma Factory	Valid
DALACIN C 150 MG CAPS	150 mg	Capsule, hard · Oral use	16 Blister	SAR 18.10	NCE · Prescription	PFIZER HOLDING FRANCE	Valid
DALACIN C 300MG CAPS	300 mg	Capsule, hard · Oral use	16 Blister	SAR 32.80	Generic · Prescription	PFIZER HOLDING FRANCE	Valid
DALACIN T LOTION 1%	1 %	Lotion · Topical	1 Bottle	SAR 19.55	Generic · Prescription	PFIZER INC	Valid
DALACIN VAGINAL CREAM 2%	2 %	Vaginal cream · Vaginal use	1 Vaginal Sponge Applicator	SAR 35.80	Generic · Prescription	PFIZER INC	Valid
DALACIN-C 150 mg/ml ampoule	150 mg/ml	Solution for injection · Intravenous use	1 Ampoule	SAR 27.65	NCE · Prescription	PFIZER	Valid
DALACIN-C 150 mg/ml ampoule	150 mg/ml	Solution for injection · Intravenous use	1 Ampoule	SAR 14.55	NCE · Prescription	PFIZER	Valid
DERMA T 10MG TOPICAL LOTION	10 mg/ml	Emulsion · Topical	1 Bottle	SAR 22.15	Generic · Prescription	Tabuk Pharmaceutical Manufacturing Company	Valid
DERMA-T SOLUTION	10 mg/ml	Solution · Topical	1 Bottle	SAR 22.15	Generic · Prescription	Tabuk Pharmaceutical Manufacturing Company	Valid
KLENDAM	300 mg	Capsule · Oral use	16 Blister	SAR 27.90	Generic · Prescription	AJA PHARMACEUTICAL INDUSTRIES	Valid
Lindacil	300 mg	Capsule · Oral use	16 Blister	SAR 27.90	Generic · Prescription	Alrai Pharmaceutical industry Co. (L.L.C)	Valid
Lindacil	150 mg	Capsule · Oral use	16 Blister	SAR 17.10	Generic · Prescription	Alrai Pharmaceutical industry Co. (L.L.C)	Valid
MEDACIN -T 1% GEL	1 %	Gel · Topical	1 Tube	SAR 16.70	Generic · Prescription	MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES	Valid
MEDACIN -T 1% TOPICAL SOLUTION	10 mg/ml	Cutaneous solution · Topical	1 Bottle	SAR 19.95	Generic · Prescription	MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES	Valid
CLINDAMYCIN PHOSPHATE 150MG-ML INJ	150 mg/ml	Solution for injection · Intravenous use	1 Vial	SAR 11.60	Generic · Prescription	HOSPIRA INC	Withdrawn by MAH · Not Marketed
CLINDAMYCIN PHOSPHATE 150MG-ML INJ	150 mg/ml	Solution for injection · Intravenous use	1 Vial	SAR 31.65	Generic · Prescription	HOSPIRA INC	Withdrawn by MAH · Not Marketed
CLINDAMYCIN PHOSPHATE 150MG-ML INJ	150 mg/ml	Solution for injection · Intravenous use	1 Vial	SAR 21.10	Generic · Prescription	HOSPIRA INC	Withdrawn by MAH · Not Marketed
CLINDAMYCIN-T 1% TOPICAL SOLN.	10 mg/ml	Cutaneous solution · Topical	1 Bottle	SAR 26.60	Generic · Prescription	UNITED PHARMACEUTICAL CO.	Withdrawn by MAH · Not Marketed
CLINDAMYCIN-T 1% TOPICAL SOLN.	10 mg/ml	Solution · Topical	1 Bottle	SAR 17.10	Generic · Prescription	UNITED PHARMACEUTICAL CO.	Withdrawn by MAH · Not Marketed
CLINIMYCIN-T	10 mg/ml	Solution · Topical	1 Bottle	SAR 23.10	Generic · Prescription	HAYAT PHARMACEUTICAL INDUSTRIES	Invalid · Not Marketed
CLINIMYCIN-T	1 %	Gel · Topical	1 Tube	SAR 23.10	Generic · Prescription	HAYAT PHARMACEUTICAL INDUSTRIES	Withdrawn by MAH · Not Marketed

6 more — full table

Indications — CHI Daman Drug Formulary

BACTERIAL GENITAL TRACT INFECTIONS

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
CLEOCIN HYDROCHLORIDE	EQ 75MG BASE; EQ 150MG BASE; EQ 300MG BASE	capsule · oral	PFIZER	Prescription	22 Feb 1970
CLEOCIN PHOSPHATE	EQ 150MG BASE/ML	injectable · injection	PFIZER	Prescription	2 Oct 1972
CLEOCIN	EQ 75MG BASE/5ML	for solution · oral	PFIZER	Prescription	7 Apr 1986
CLEOCIN T	EQ 1% BASE	gel · topical	PFIZER	Prescription	7 Jan 1987
CLEOCIN PHOSPHATE	EQ 150MG BASE/ML	injectable · injection	PFIZER	Prescription	16 Oct 1987
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	injectable · injection	HIKMA PHARMS	Prescription	25 Apr 1988
CLEOCIN T	EQ 1% BASE	lotion · topical	PFIZER	Prescription	31 May 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%	EQ 900MG BASE/100ML	injectable · injection	ABRAXIS PHARM	Prescription	22 Dec 1989
CLEOCIN	EQ 2% BASE	cream · vaginal	PFIZER	Prescription	11 Aug 1992
CLINDAMYCIN PHOSPHATE	EQ 1% BASE	solution · topical	PADAGIS US	Prescription	30 Nov 1995
CLINDAMYCIN PHOSPHATE	EQ 1% BASE	solution · topical	FOUGERA PHARMS INC	Prescription	5 Jun 1997
CLEOCIN	100MG	suppository · vaginal	PFIZER	Prescription	13 Aug 1999
CLINDAMYCIN PHOSPHATE	EQ 1% BASE	gel · topical	FOUGERA PHARMS	Prescription	28 Jan 2000
CLINDAMYCIN PHOSPHATE	EQ 1% BASE	swab · topical	PADAGIS US	Prescription	25 May 2000
CLINDAGEL	EQ 1% BASE	gel · topical	BAUSCH	Prescription	27 Nov 2000
CLINDAMYCIN HYDROCHLORIDE	EQ 150MG BASE; EQ 300MG BASE	capsule · oral	SUN PHARM INDS LTD	Prescription	2 Feb 2001
CLINDAMYCIN PHOSPHATE	EQ 1% BASE	lotion · topical	FOUGERA PHARMS	Prescription	31 Jan 2002
CLINDAMYCIN HYDROCHLORIDE	EQ 150MG BASE; EQ 300MG BASE	capsule · oral	EPIC PHARMA LLC	Prescription	22 Mar 2004
CLINDAMYCIN PHOSPHATE	EQ 1% BASE	solution · topical	TARO PHARM INDS	Prescription	31 Mar 2004
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	injectable · injection	HIKMA PHARMS	Prescription	24 Sep 2004
CLINDESSE	EQ 2% BASE	cream · vaginal	PADAGIS US	Prescription	30 Nov 2004
CLINDAMYCIN PHOSPHATE	EQ 2% BASE	cream · vaginal	FOUGERA PHARMS	Prescription	27 Dec 2004
CLINDAMYCIN HYDROCHLORIDE	EQ 75MG BASE; EQ 150MG BASE; EQ 300MG BASE	capsule · oral	ZYDUS PHARMS USA	Prescription	31 Jan 2005
CLINDAMYCIN HYDROCHLORIDE	EQ 75MG BASE; EQ 150MG BASE	capsule · oral	LANNETT	Prescription	12 Aug 2005
CLINDAMYCIN HYDROCHLORIDE	EQ 75MG BASE	capsule · oral	CHARTWELL MOLECULAR	Prescription	12 Aug 2005

93 more — full table

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
AURO-CLINDAMYCIN	02436906	150 MG	CAPSULE · ORAL	AURO PHARMA INC
AURO-CLINDAMYCIN	02436914	300 MG	CAPSULE · ORAL	AURO PHARMA INC
CLINDAMYCIN	02400529	150 MG	CAPSULE · ORAL	SANIS HEALTH INC
CLINDAMYCIN	02400537	300 MG	CAPSULE · ORAL	SANIS HEALTH INC
CLINDAMYCIN INJECTION IN 5% DEXTROSE	02485478	600 MG / 50 ML	SOLUTION · INTRAVENOUS	BAXTER CORPORATION
CLINDAMYCIN INJECTION IN 5% DEXTROSE	02485486	900 MG / 50 ML	SOLUTION · INTRAVENOUS	BAXTER CORPORATION
CLINDAMYCIN INJECTION USP	02230535	150 MG / ML	SOLUTION · INTRAVENOUS	SANDOZ CANADA INCORPORATED
CLINDAMYCIN INJECTION USP	02230540	150 MG / ML	LIQUID · INTRAVENOUS; INTRAMUSCULAR	SANDOZ CANADA INCORPORATED
CLINDAMYCIN IV INFUSION	02408511	12 MG / ML	SOLUTION · INTRAVENOUS	SANDOZ CANADA INCORPORATED
CLINDAMYCIN IV INFUSION	02408538	18 MG / ML	SOLUTION · INTRAVENOUS	SANDOZ CANADA INCORPORATED
DALACIN C FLAVOURED GRANULES	00225851	75 MG / 5 ML	GRANULES FOR SOLUTION · ORAL	PFIZER CANADA ULC
JAMP CLINDAMYCIN	02483734	150 MG	CAPSULE · ORAL	JAMP PHARMA CORPORATION
JAMP CLINDAMYCIN	02483742	300 MG	CAPSULE · ORAL	JAMP PHARMA CORPORATION
JAMP CLINDAMYCIN CAPSULES	02557878	150 MG	CAPSULE · ORAL	JAMP PHARMA CORPORATION
JAMP CLINDAMYCIN CAPSULES	02557886	300 MG	CAPSULE · ORAL	JAMP PHARMA CORPORATION
M-CLINDAMYCIN	02479923	150 MG	CAPSULE · ORAL	MANTRA PHARMA INC
M-CLINDAMYCIN	02479931	300 MG	CAPSULE · ORAL	MANTRA PHARMA INC
MED-CLINDAMYCIN	02462656	150 MG	CAPSULE · ORAL	GENERIC MEDICAL PARTNERS INC
MED-CLINDAMYCIN	02462664	300 MG	CAPSULE · ORAL	GENERIC MEDICAL PARTNERS INC
NRA-CLINDAMYCIN	02493748	150 MG	CAPSULE · ORAL	NORA PHARMA INC
NRA-CLINDAMYCIN	02493756	300 MG	CAPSULE · ORAL	NORA PHARMA INC
RIVA-CLINDAMYCIN	02468484	300 MG	CAPSULE · ORAL	LABORATOIRE RIVA INC.
TARO-CLINDAMYCIN	02266938	1 % / W/V	SOLUTION · TOPICAL	TARO PHARMACEUTICALS INC
TEVA-CLINDAMYCIN	02241709	150 MG	CAPSULE · ORAL	TEVA CANADA LIMITED
TEVA-CLINDAMYCIN	02241710	300 MG	CAPSULE · ORAL	TEVA CANADA LIMITED

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	CLEOCIN 100 MG VAGINAL OVULE	$60.17905	per EA	23 Sep 2026
US NADAC	CLEOCIN 2% VAGINAL CREAM	$1.79228	per GM	23 Sep 2026
US NADAC	CLINDAMYCIN (PEDI) 75 MG/5 ML	$0.12876	per ML	23 Sep 2026
US NADAC	CLINDAMYCIN 2% VAGINAL CREAM	$1.85916	per GM	23 Sep 2026
US NADAC	CLINDAMYCIN HCL 150 MG CAPSULE	$0.1028	per EA	23 Sep 2026
US NADAC	CLINDAMYCIN HCL 300 MG CAPSULE	$0.17458	per EA	23 Sep 2026
US NADAC	CLINDAMYCIN HCL 75 MG CAPSULE	$0.25869	per EA	23 Sep 2026
US NADAC	CLINDAMYCIN PH 1% GEL	$0.14236	per GM	23 Sep 2026
US NADAC	CLINDAMYCIN PH 1% GEL	$0.13074	per GM	23 Sep 2026
US NADAC	CLINDAMYCIN PH 1% SOLUTION	$0.1788	per ML	23 Sep 2026
US NADAC	CLINDAMYCIN PH 1% SOLUTION	$0.14989	per ML	23 Sep 2026
US NADAC	CLINDAMYCIN PHOS 1% PLEDGET	$0.28544	per EA	23 Sep 2026
NHS Drug Tariff	Clindamycin 1% aqueous lotion	£5.08	30 ml	1 Oct 2026
NHS Drug Tariff	Clindamycin 1% gel	£9.95	30 gram	1 Oct 2026
NHS Drug Tariff	Clindamycin 150mg capsules	£1.82	24 capsule	1 Oct 2026
NHS Drug Tariff	Clindamycin 2% vaginal cream	£10.86	40 gram	1 Oct 2026
NHS Drug Tariff	Clindamycin 300mg capsules	£4.74	30 capsule	1 Oct 2026
NHS Drug Tariff	Clindamycin 75mg capsules	£7.45	24 capsule	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

WHO WHO Model List of Essential Medicines (2025)

6.2.1. Access group antibiotics · core
First choice: Necrotising fasciitis; Second choice: Bacterial infection of joint; Second choice: Osteomyelitis or osteitis
Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate) (EML); 900 mg per 6 mL (as phosphate) (EML) | Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) (EMLc) | Oral > Solid: 150 mg (as hydrochloride)

Safety signals and safety-related labeling changes

US FDA 1 Sep 2026 CLEOCIN HYDROCHLORIDE — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
US FDA 26 Mar 2026 CLEOCIN PHOSPHATE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations
US FDA 12 Nov 2025 CLEOCIN T — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations
US FDA 12 Nov 2025 CLEOCIN T — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations
US FDA 12 Nov 2025 CLEOCIN T — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations
US FDA 30 Jan 2025 CLINDESSE — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
US FDA 6 Mar 2023 XACIATO — safety-related labeling change
Labeling sections changed: Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide
US FDA 17 May 2022 CLEOCIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations
US FDA 17 May 2022 CLEOCIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations
EMA PRAC 6 May 2021 PRAC signal: Acute renal failure
Action for MAH: update of the product information: Yes
EMA PRAC 14 Jan 2021 PRAC signal: Acute renal failure
Action for MAH: update of the product information: No
US FDA 21 Feb 2020 ONEXTON — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
US FDA 17 Apr 2018 EVOCLIN — safety-related labeling change
Labeling sections changed: Use in Specific Populations
EMA PRAC 10 Apr 2014 PRAC signal: Drug interaction with warfarin leading to international normalised ratio (INR) increased
Action for MAH: update of the product information: Yes
EMA PRAC 5 Dec 2013 PRAC signal: Drug interaction with warfarin leading to international normalised ratio (INR) increased
Action for MAH: update of the product information: No

All safety entries for clindamycin →

Combinations containing Clindamycin

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.